id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2232-0007,FDA,FDA-2020-E-2232,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-08-29T04:00:00Z,2022,8,2022-08-29T04:00:00Z,,2022-08-29T17:22:45Z,,0,0,0900006485287606
FDA-2020-E-2232-0006,FDA,FDA-2020-E-2232,Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI,Notice,Determinations,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,2022-01-11T04:59:59Z,2024-02-05T19:20:20Z,2021-24435,0,0,0900006484e37a46
FDA-2020-E-2232-0005,FDA,FDA-2020-E-2232,Patent Term Extension letter from FDA CDER to The Honorable Drew Hirshfield,Other,Letter(s),2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,,2021-11-05T14:52:29Z,,0,0,0900006484e2590c
FDA-2020-E-2232-0004,FDA,FDA-2020-E-2232,Patent Term Extension Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T16:52:28Z,,0,0,0900006484c0ef19
FDA-2020-E-2232-0003,FDA,FDA-2020-E-2232,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T20:13:59Z,,0,0,090000648499d78c
FDA-2020-E-2232-0001,FDA,FDA-2020-E-2232,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2020-11-25T16:43:02Z,,0,0,09000064849763f6
FDA-2020-E-2232-0002,FDA,FDA-2020-E-2232,"Patent Extension Application from Cooley LLP (on behalf of Ultragenyx Pharmaceutical, Inc.)",Other,Application,2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2020-11-25T16:43:11Z,,0,0,09000064849763f7